Abarelix (Plenaxis) for the treatment of advanced hormone-dependent prostate cancer
Data from two head-to-head trials showed that abarelix was not inferior to the GnHR-agonist leuprolide. The unintended effects of abarelix are
comparable with the unintended effects of the GnRH-agonists and degarelix. In addition, there are no clinically important differences in the applicability or ease of use between these agents. Unlike the GnRH-agonists, data on the long-term intended (e.g., survival) and unintended effects are not available for abarelix.
For the treatment of adult male patients with advanced or metastatic castrate resistant (hormone refractory) prostate cancer, the therapeutic value of abarelix is comparable with that of the GnRH-agonists leuprolide, buserelin, goserelin and triptorelin en the GnRH-antagonist degarelix.